University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
USDA Wildlife Services - Staff Publications

U.S. Department of Agriculture: Animal and
Plant Health Inspection Service

2013

Humoral immune response to oral rabies vaccination in raccoon
kits: Problems and implications
Tricia L. Fry
USDA/APHIS/Wildlife Services’ National Wildlife Research Center, tricia.l.fry@aphis.usda.gov

Kaci K. VanDalen
USDA/APHIS/WS National Wildlife Research Center, kaci.vandalen@aphis.usda.gov

Susan A. Shriner
USDA/APHIS/WS National Wildlife Research Center, susan.a.shriner@aphis.usda.gov

Susan M. Moore
Kansas State University Rabies Laboratory, smoore@vet.k-state.edu

Cathleen A. Hanlon
Kansas State University Rabies Laboratory, chanlon@vet.k-state.edu

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc

Fry, Tricia L.; VanDalen, Kaci K.; Shriner, Susan A.; Moore, Susan M.; Hanlon, Cathleen A.; and Vercauteren,
Kurt C., "Humoral immune response to oral rabies vaccination in raccoon kits: Problems and implications"
(2013). USDA Wildlife Services - Staff Publications. 1228.
https://digitalcommons.unl.edu/icwdm_usdanwrc/1228

This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant
Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion
in USDA Wildlife Services - Staff Publications by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.

Authors
Tricia L. Fry, Kaci K. VanDalen, Susan A. Shriner, Susan M. Moore, Cathleen A. Hanlon, and Kurt C.
Vercauteren

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
icwdm_usdanwrc/1228

Vaccine 31 (2013) 2811–2815

Contents lists available at SciVerse ScienceDirect

Vaccine
journal homepage: www.elsevier.com/locate/vaccine

Humoral immune response to oral rabies vaccination in raccoon kits: Problems
and implications
Tricia L. Fry a , Kaci K. VanDalen a,∗ , Susan A. Shriner a , Susan M. Moore b , Cathleen A. Hanlon b ,
Kurt C. VerCauteren a
a
United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, 4101 Laporte Ave, Fort Collins, Colorado
80521, USA
b
Kansas State University Rabies Laboratory, 2005 Research Park Circle, Manhattan, Kansas 66502, USA

a r t i c l e

i n f o

Article history:
Received 15 January 2013
Received in revised form 4 April 2013
Accepted 7 April 2013
Available online 18 April 2013
Keywords:
Raccoon kits
Oral rabies vaccination
Procyon lotor
Rabies
Raboral V-RG
Maternal antibodies

a b s t r a c t
Little is known about the immunogenicity of RABORAL V-RG® (V-RG), an oral rabies vaccine, in raccoon
kits (Procyon lotor). The objectives of this study were to characterize the immunogenicity of V-RG in young
kits and investigate the potential impact of maternal antibodies on response to vaccination of nursing
raccoon kits. Raccoon kits (n = 30) were vaccinated at either 3 weeks of age, 7 weeks of age, or assigned
as contact controls. Nineteen kits (73%) that were whelped by unvaccinated mothers responded to VRG exposure (orally or indirect contact) by production of detectable rabies virus neutralizing antibodies
(RVNA) while 7 (27%) kits did not respond to V-RG exposure. Four kits were whelped by a mother with
high levels of RVNA and all four kits acquired maternal rabies antibodies. At approximately 9 months of
age, all kits were inoculated with a killed rabies vaccine, IMRAB3® . The kits which initially responded to
V-RG oral vaccination or contact with vaccinated littermates demonstrated a rapid anamnestic response.
In contrast, the V-RG non-responders and those with acquired maternal antibodies exhibited a primary
immune response to IMRAB3® , where RVNA levels were substantially lower on days 5 and 7 than the
levels in the animals with an anamnestic response. These ﬁndings suggest that the naïve contact kits
and the nonresponsive kits most likely remained susceptible to rabies virus infection whereas the ones
demonstrating response to V-RG would not have been susceptible to a rabies virus infection.
Published by Elsevier Ltd.

1. Introduction
Rabies is one of the oldest diseases described with records of
clinical manifestations in humans dating back to 2300 B.C. It is
estimated that more than 55,000 people die of rabies each year
and another 20 million receive rabies post exposure prophylaxis
[1]. Throughout most of the world, domestic dogs remain the
most common reservoir for local transmission of canine-associated
rabies virus variants; however, in the United States the dominant
virus variants are associated with wildlife species [2]. Rabies viruses
consist of a number of unique variants that are adapted to speciﬁc
hosts [3]. The animals most frequently reported with rabies in the
United States are raccoons (Procyon lotor), insectivorous bats (Chiroptera spp.), striped skunks (Mephitis mephitis), foxes of several
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species (Vulpes lagopus, Vulpes vulpes, and Urocyon cinereoargenteus), and coyotes (Canis latrans) [4,5]. As an augment to traditional
reactive public health measures, oral rabies vaccination (ORV)
campaigns have been implemented on an experimental basis in
strategic locations in an attempt to control the spread of expanding terrestrial epizootics. The effectiveness of ORV programs, most
notably those directed toward control of rabies virus variants in
Europe and North America has been previously reviewed [6,7].
The National Rabies Management Program, administered by
USDA-APHIS Wildlife Services, is tasked with controlling the spread
of terrestrial wildlife-associated rabies in the United States. At
present, the majority of ORV efforts involve the distribution of
a live recombinant vaccine, RABORAL V-RG® (V-RG, Merial Inc.,
Athens, GA, USA). V-RG is currently the only effective oral vaccine
licensed for use in free-ranging raccoons and coyotes in the United
States [8]. In the eastern United Sates, the main focus of ORV campaigns is the raccoon rabies variant, which has spread and evolved
since the 1970s into a widespread epizootic [9,10]. As a consequence of wildlife translocation from the southeast United States
raccoon rabies was introduced into the Mid-Atlantic States and now
extends north into Canada and across the Appalachian mountains
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as far west as Ohio [11]. Generally, raccoon ORV campaigns with
V-RG commence in late summer or early fall when raccoon population density peaks [12]. While considerable research has been
done on vaccination of adult raccoons, few published studies are
available on the vaccine’s immunogenicity and efﬁcacy in young
raccoons. Rupprecht et al. reported that three suckling raccoon
kits (3–4 weeks olds) seroconverted within 28 days after their
mother was orally vaccinated with V-RG, although the mode of
transmission, either grooming or lactation was not ascertained.
Subsequently, all three kits survived a rabies virus challenge [13].
Maternal antibodies can be passively transferred to young through
the placenta, yolk sac, colostrum, and/or milk [14] depending upon
the species and the type of placentation and other aspects of the
species physiology. Maternal neutralizing antibodies to rabies virus
(≥0.5 IU/mL) can circulate for several weeks in fox cubs [15–17].
Blasco et al. [15] observed the disappearance of maternal antibodies in fox cubs corresponded to approximately 10–20 days after
weaning. The duration of maternally derived antibodies to rabies
virus in raccoon kits has not been published but may be similar
to the half-life of raccoon maternal antibodies to canine distemper virus, which is approximately 10.55 days post-weaning [18].
While the role of maternal antibodies is to protect a young animal
with an immature immune system from harmful pathogens, it has
been shown that the presence of circulating maternal antibodies
in young animals may interfere with the response to some vaccinations [18–20]. Research examining the maternal antibody-rabies
vaccination interference in wildlife has been limited to reports in
red foxes with Blasco et al. [15] reporting that maternal immune
status did not interfere with the oral rabies vaccination of cubs once
maternal antibodies disappeared (<0.5 IU/mL) between 45 and 75
days old.
The speciﬁc objectives of this study were to: (1) monitor rabies
virus neutralization antibody (RVNA) levels in very young raccoon
kits following exposure to V-RG, (2) determine a raccoon kit’s ability to produce an anamnestic response following a second exposure
to the rabies antigen (in this case, the killed rabies vaccine IMRAB3®
(Merial Inc., Athens, GA, USA)), (3) determine how long maternally
derived antibodies circulate in young raccoons and, (4) demonstrate whether or not maternal antibodies to rabies virus interfere
with V-RG vaccination.

2. Materials and methods
2.1. Study animals
As the result of another research project seven wild caught
female raccoons became pregnant and whelped at least one kit.
The female raccoons were trapped from within Larimer County,
Colorado, USA and housed in the Outdoor Animal Research Facility at the USDA APHIS WS National Wildlife Research Center
(NWRC), Fort Collins, CO, USA. Three of the females with litters
had been previously vaccinated with IMRAB3® , a killed rabies vaccine. Of the three vaccinated females, only one had detectable RVNA
(14.4 IU/mL) one month prior to whelping. Four kits were born and
weaned by this female. The four females which were not vaccinated
and the two IMRAB3® vaccinates that did not have detectable RNVA
(<0.1 IU/mL) whelped a total of 26 raccoon kits.
Raccoon kits were housed with their mothers for ≥14 weeks, but
not >17 weeks. Raccoon kits remained with litter mates for three
weeks after weaning, at which time they were moved to individual
pens. Raccoons were held in accordance with IACUC guidelines, and
fed a varying, age appropriate diet that included Omnivore Diet
A (Mazouri, St. Louis, MO, USA), milk replacer, canned cat food,
mackerel, eggs, and various fresh fruits. Water was provided ad
libitum.

2.2. Blood collection
We collected blood from each adult female raccoon approximately one month prior to whelping and again at weaning. We
used 5:1 ketamine (10 mg/kg) and xylazine (2 mg/kg) mixture [21]
to anesthetize adult raccoons and collected blood [22]. Starting at
10–14 days old we collected blood weekly for 26 weeks from raccoon kits. Blood collection and restraint techniques varied based on
the age of the raccoon kits. Raccoon kits were primarily physically
restrained or anesthetized using isoﬂurane until they were housed
individually. Once housed individually we anesthetized raccoons
using a 5:1 ratio of ketamine: xylazine as described above. We collected blood samples via the jugular vein with volumes ranging
from 0.4 mL to 3 mL (≤1.5% body mass) [22] in Vacutainer SST®
serum separator tubes (Becton Dickinson, Franklin Lakes, NJ, USA).
We stored sera at −80 ◦ C until it was sent to the Kansas State University Rabies Laboratory (Manhattan, KS, USA) for testing.
2.3. Primary vaccination
We arbitrarily assigned raccoon kits into one of three treatment
groups: (1) vaccinated with V-RG at 3 weeks of age, (2) vaccinated
at 7 weeks of age, or (3) unvaccinated (contact controls). Six litters
had at least one representative of each group, except for one litter
which consisted of a single kit that was vaccinated at 3 weeks of
age. Vaccination consisted of 1.5 mL (108.2 PFU) V-RG administered
orally via needleless syringe (Lot #576-151, Merial, Ltd., Athens,
GA, USA). Immediately after vaccination, we returned kits to their
mothers and litter mates.
2.4. Secondary vaccination to assess anamnestic responses
An anmnestic response to the rabies virus after oral vaccination
has been previously shown to increase the likelihood of raccoon
survival [23]. To evaluate young raccoons’ responses to a second rabies antigen exposure (in this case, a killed rabies vaccine,
IMRAB3® ), we inoculated all raccoon kits with IMRAB3® (Serial:
12550, Merial, Ltd. Athens, GA, USA), between 38 and 41 weeks of
age. We collected blood as previously described on days 0, 5, 7, and
31 post-IMRAB3® inoculation (time points were designated as B0,
B5, B7, and B31). We used a Student’s t-test to evaluate an anamnestic response by comparing the differences in median RVNA values
between B0 and (1) day B5, (2) day B7, and (3) day B31.
2.5. Laboratory testing
We sent aliquots of serum to Kansas State University Rabies
Laboratory for detection and quantiﬁcation of RVNA. RVNA were
characterized by the Rapid Fluorescent Focus Inhibition Test
(RFFIT); the 50% end point titer of the test serum was converted
to IU/mL values by comparison to the 50% end point titer of the U.S.
Standard Rabies Immune Globulin, Lot R-3, 59 IU (1st WHO International Standard), which is measured in the same assay run, with
an assigned value of 2.0 IU/mL [24,25]. Sero-status of raccoons was
determined based on a detection threshold of 0.1 IU/mL to increase
sensitivity [26].
3. Results
3.1. Antibody responses of raccoon kits after initial vaccination
Six litters (n = 26 kits) were whelped by seronegative mothers and subsequently had no detectable RVNA 2–3 weeks after
birth. Ten of these raccoon kits were vaccinated at 3 weeks of
age and nine (90%) developed RVNA at an average of 5.2 weeks
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Fig. 1. RVNA proﬁle of raccoon kits vaccinated with V-RG at 3 weeks of age. Nine of ten raccoon kits without maternal antibodies responded to VR-G vaccination by producing
RVNA ≥0.1 IU/mL for at least ﬁve consecutive weeks. RVNA levels varied between individuals; seven kits still had detectable RVNA at 26 weeks post-vaccination.

Fig. 2. RVNA proﬁle of raccoon kits vaccinated with V-RG at 7 weeks of age. Six of eight raccoon kits without maternal antibodies responded to VR-G vaccination by producing
RVNA ≥0.1 IU/mL for at least ﬁve consecutive weeks. RVNA levels varied between individuals; four kits still had detectable RVNA at 26 weeks post-vaccination.

of age (range = 4–6 weeks; Fig. 1). Eight raccoon kits were vaccinated at 7 weeks of age and 6 (75%) developed RVNA at an average
of 8.6 weeks of age (Range = 5–17 weeks; Fig. 2). Eight raccoon kits
were not orally vaccinated and served as contact controls; four of
these kits (50%) developed RVNA at an average of 6.25 weeks of
age (Range = 5–9 weeks; Fig. 3). All raccoon kits that seroconverted
(n = 19) had detectable levels of RVNA for at least ﬁve consecutive weeks. Thirteen of these raccoon kits (68%) still had detectable
RVNA at 26 weeks of age (one RVNA positive kit was euthanized on
week 10 due to a pelvic deformity).
One litter (n = 4 kits) was whelped by a mother with detectable
RVNA one month before whelping (14.4 IU/mL) and at weaning
(4.3 IU/mL). All four kits had high levels of RVNA (≥8.0 IU/mL)

at the ﬁrst blood sampling (12 days old; Fig. 4). After 3 weeks
of age, RVNA levels of all four kits ﬂuctuated between 8.0 IU/mL
and 15 IU/mL for several weeks until levels steadily declined from
10 to 12 weeks through week 26. By 26 weeks (11 weeks after
weaning), 3 of 4 kits with maternally acquired antibodies still had
detectable RVNA values of 0.1 IU/mL, while 1 kit had no detectable
RVNA.
3.2. Immune responses of raccoon kits after second exposure to
rabies vaccine
Overall, 19/26 kits (73%) that were whelped by seronegative
mothers and exposed to V-RG produced RVNA levels of ≥0.1 IU/mL

Fig. 3. RVNA proﬁle of contact raccoon kits. Four of eight raccoon kits without maternal antibodies produced RVNA ≥0.1 IU/mL for at least ﬁve consecutive weeks after
exposure to vaccinated littermates. RVNA levels varied between individuals; two kits still had detectable RVNA at 26 weeks post-vaccination.
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4. Discussion
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Fig. 4. RVNA proﬁle of raccoon kits with maternally acquired antibodies. All four
individuals exhibit a similar RVNA curve regardless of V-RG vaccination. At 26 weeks
three raccoon kits still had detectable RVNA of 0.1 IU/mL. The raccoon kit vaccinated
at 7 weeks had undetectable RVNA at 26 weeks.

Fig. 5. RVNA proﬁle of raccoon kits after a secondary rabies antigen exposure
(IMRAB3® ). All kits had previously been exposed to V-RG (orally or contact) and were
designated as “Responders”, “Non-responders”, and “Kits with maternally acquired
Abs” based on their primary response. Kits that responded initially to the V-RG exposure (RVNA ≥0.1 IU/mL) appeared to have an anamnestic response to the IMRAB3® ,
while the other kits may have had a primary response.

for at least ﬁve consecutive weeks (designated as “responders”). Of
the 19 responders, 15 were orally vaccinated and 4 were contact
controls. Seven of 26 kits (30%) failed to produce RVNA levels of
≥0.1 IU/mL (designated as “non-responders”). Following the subsequent vaccination with the killed rabies vaccine, IMRAB3® , we
measured RVNA levels to assess any possible amnestic responses.
“Responders” and “non-responders” differed signiﬁcantly between
day B0 and B5 and between day B0 and B7 (P < 0.05). No difference
was observed between “responders” and “non-responders” by day
B31. The 4 kits with maternally acquired antibodies had a similar
RVNA proﬁle as the “non-responders” (Fig. 5).

Vaccination of young animals can be problematic. First, depending on species and age, their immune system may still be relatively
immature and secondly, they may still have circulating antibodies
acquired from their mothers that may interfere with vaccinations
[16,18–20]. This is the ﬁrst study to monitor the RVNA responses
of very young raccoons (3–7 weeks of age) to V-RG and subsequent
rabies vaccine exposure.
Twenty-six raccoon kits were whelped by mothers without
detectable RVNA. While 90% of kits vaccinated at 3 weeks of age
developed detectable RVNA (≥0.1 IU/mL) and 75% of kits vaccinated at 7 weeks of age developed detectable RVNA, the relatively
low sample size does not have the statistical power to differentiate these two treatment groups. However, it appears that very
young kits vaccinated at 3 weeks old responded as well as or better
than kits vaccinated at 7 weeks old. In fact, of the 6 responders that
were vaccinated at 7 weeks, three (50%) developed RVNA at 5 weeks
of age, suggesting that they were actually “vaccinated” by contact
with 3 week vaccinates. Interestingly, 50% of our non-vaccinated
contact kits also developed detectable levels of RVNA. These contact
kits were most likely exposed to V-RG from suckling or playing with
vaccinated kits. Limited horizontal transmission has previously
been documented in other oral rabies vaccine experimental studies [13,27,28]. We did not observe any signs of disease or adverse
effects associated with vaccination of these young animals and the
overall seroconversion rate was similar to what we have observed
in experimentally vaccinated adult raccoons [29]. Regardless of
vaccination treatment, kits that developed RVNA also showed an
anamnestic response after exposure to IMRAB3® at 38–41 weeks
of age. Although we did not challenge the young raccoons with
live rabies virus in this study, an anamnestic response to the rabies
virus after oral vaccination has been previously shown to increase
the likelihood of raccoon survival [23].
Because ORV baits are often dispersed in late summer/early
autumn and because RVNA can still be detected in adult raccoons
for many months after vaccination [30,31] it is possible that females
would pass on maternal rabies antibodies to their young in the
spring/summer. Three previous studies demonstrated that some
fox cubs (Vulpes vulpes) born of rabies vaccinated mothers had
detectable levels of RVNA in their serum for months [15–17], probably dependent on time of weaning. Two of our goals were to monitor
the levels of maternally acquired antibodies in raccoon kits and
investigate possible interference with oral rabies vaccination. Only
a single mother had detectable RVNA one month prior to whelping
so our ability to determine the importance of maternal antibody
interference was limited to the analysis of four raccoon kits. We
were unable to collect blood from the mother while she was nursing
the kits. However, we were able to determine her RVNA levels one
month prior to whelping (14.4 IU/mL) and when kits were weaned
at 15 weeks (4.3 IU/mL), levels adequate to allow antibody transfer
during lactation. Regardless of vaccination treatment, the four kits
whelped by this vaccinated mother had similar RVNA curves that
ﬂuctuated between 8.0 IU/mL and 15 IU/mL for several weeks until
levels steadily declined through week 26. Three out of four kits still
had detectable RVNA at nine weeks post-weaning. If these RVNA
were solely maternally derived (and not affected by active vaccination) then the half-life of maternal RVNA was approximately
10.5 days after weaning. This ﬁnding would be consistent with
the duration of maternally acquired canine distemper virus (CDV)
neutralizing antibodies, which had a half-life of 10.55 days after
weaning [18].
Pare et al. [18] also showed that CDV neutralizing antibodies will nullify or interfere with subsequent CDV vaccination of
raccoons at 8 weeks of age. Similarly, fox cubs with maternal RVNA
(≥0.5 IU/mL) showed a signiﬁcantly lower response to vaccination
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with an oral live attenuated vaccine SAD B19 (at 4–7 weeks) than
fox cubs without maternal RVNA, suggesting that the maternal
antibodies interfered with vaccination [16]. Another study demonstrated that fox cubs vaccinated with V-RG at 30 days or 90 days
of age mounted similar immune responses regardless of the age at
vaccination or immune status of the their mothers suggesting that
no interference existed between passive immunity of maternal origin and active immunity conferred by V-RG oral vaccination [15].
However, in this study [15] all but one pup had maternally acquired
RVNA values less than the threshold of the assay (0.5 IU/mL) at the
time of vaccination.
To determine whether or not maternally acquired antibodies
interfered with V-RG vaccination of raccoon kits, we looked for
an anamnestic response to a second vaccination with IIMRAB3® .
While kits that responded to the ﬁrst vaccination (RVNA levels of
≥0.1 IU/mL) showed a marked increase in median RVNA levels by
5 days post-IMRAB3® exposure, kits that did not respond to the
ﬁrst vaccination (RVNA levels of <0.1 IU/mL throughout sampling)
and kits that had maternally acquired antibodies exhibited a slower
increase in median RVNA levels. Although the data from this study
are limited, the results indicate that maternally acquired antibodies may interfere with a kit’s immune response to vaccination and
that further investigation is warranted.
Overall, our data suggest that raccoon kits (3–7 weeks of age)
are able to produce RVNA after oral vaccination with V-RG. These
same kits are also able to mount an anamnestic response to a
second rabies antigen exposure, which may be indicative of surviving rabies virus infection. However, it is possible that circulating
maternally derived antibodies may interfere with active V-RG
vaccination. If RVNA circulates in adult female raccoons through
whelping and maternally acquired antibodies interfere with active
immunizations then ORV programs must be cognizant of the timing ORV operations to account for this population segment of
young raccoons unaffected by vaccination. The current timeline
used by USDA APHIS Wildlife Services for ORV campaigns begins
each year in early September when most young of the year are
nearing 26 weeks old and no longer exhibiting maternally transferred antibodies, thus increasing the likelihood of success of the
vaccine at the initial exposure to V-RG. There are of course exceptions, as it is possible that raccoon kits born later in the spring
or early summer may experience interference between maternally
acquired antibodies and vaccination, decreasing the success of ORV
campaigns.
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